189 related articles for article (PubMed ID: 14520710)
21. Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissue.
Xu C; Zhou T; He M; Sun Y
Urol Oncol; 2010; 28(3):314-9. PubMed ID: 19070519
[TBL] [Abstract][Full Text] [Related]
22. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
23. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
24. [The morphogenesis of cancer of the prostate (immunohistochemical research)].
Vorobĭova LR
Lik Sprava; 1998 May; (3):87-90. PubMed ID: 9695575
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of NSAID-activated gene product in prostate cancer.
Iczkowski KA; Pantazis CG
Int J Surg Pathol; 2003 Jul; 11(3):159-66. PubMed ID: 12894347
[TBL] [Abstract][Full Text] [Related]
26. Snail1 is over-expressed in prostate cancer.
Heebøll S; Borre M; Ottosen PD; Dyrskjøt L; Orntoft TF; Tørring N
APMIS; 2009 Mar; 117(3):196-204. PubMed ID: 19245592
[TBL] [Abstract][Full Text] [Related]
27. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.
Li R; Erdamar S; Dai H; Wheeler TM; Frolov A; Scardino PT; Thompson TC; Ayala GE
Hum Pathol; 2007 Oct; 38(10):1501-7. PubMed ID: 17597184
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas.
Elmore LW; Forsythe R; Forsythe H; Bright AT; Nasim S; Endo K; Holt SE
Oncol Rep; 2008 Sep; 20(3):613-7. PubMed ID: 18695913
[TBL] [Abstract][Full Text] [Related]
29. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.
Altinok G; Powell IJ; Che M; Hormont K; Sarkar FH; Sakr WA; Grignon D; Liao DJ
Prostate Cancer Prostatic Dis; 2006; 9(1):77-82. PubMed ID: 16331298
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.
Kreisberg JI; Malik SN; Prihoda TJ; Bedolla RG; Troyer DA; Kreisberg S; Ghosh PM
Cancer Res; 2004 Aug; 64(15):5232-6. PubMed ID: 15289328
[TBL] [Abstract][Full Text] [Related]
31. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
Cardillo MR; Ippoliti F
Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
[TBL] [Abstract][Full Text] [Related]
32. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
Chua CW; Chiu YT; Yuen HF; Chan KW; Wang X; Ling MT; Wong YC
APMIS; 2010 Dec; 118(12):918-26. PubMed ID: 21091772
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
36. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens.
Qian J; Bostwick DG
Pathol Res Pract; 1995 Sep; 191(9):860-7. PubMed ID: 8606866
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
38. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
39. Trefoil factor 3 is overexpressed in human prostate cancer.
Garraway IP; Seligson D; Said J; Horvath S; Reiter RE
Prostate; 2004 Nov; 61(3):209-14. PubMed ID: 15368472
[TBL] [Abstract][Full Text] [Related]
40. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]